JAGSONPAL PHARMACEUTICALS Valuation

JAGSNPHARM · Healthcare · Current price ₹239.57

Full stock page
DocStoX fair value
₹102
low confidence
Current price
₹240
Upside
-57.3%
P/E ratio
37.3x
P/B ratio
5.7x
Verdict
Avoid
Model it yourself — Earnings Yield Calculator
Opens pre-filled with JAGSONPAL PHARMACEUTICALS's latest numbers.

Is JAGSONPAL PHARMACEUTICALS undervalued?

DocStoX estimates the fair value of JAGSONPAL PHARMACEUTICALS at ₹102 per share, versus the current market price of ₹240. That puts the stock about -57.3% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is low.

How this fair value is calculated

This estimate blends 3 independent methods: Residual income (₹43), Relative P/E (₹235), Graham floor (₹77). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.

Bear, base and bull scenarios

Our scenarios span ₹43 (bear) to ₹102 (base) to ₹235 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.

Valuation multiples

JAGSONPAL PHARMACEUTICALS trades at a P/E of 37.3x and a P/B of 5.7x, with a dividend yield of 1.7%. Multiples are most useful compared against the company's own history and its sector peers — see the peer comparison for context.

Understand the ratios

P/E RatioP/B RatioPEG RatioEarnings Yield

More on JAGSONPAL PHARMACEUTICALS

Fair ValueIntrinsic ValueDCFFinancial RatiosPeers

DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.